Related Experiment Videos
[Clinical picture and therapy of hypertrophic cardiomyopathy]
1Kardiologische Klinik, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Bad Oeynhausen.
Insights
Hypertrophic cardiomyopathy (HCM) is a heart muscle disease causing outflow tract obstruction. Percutaneous transluminal septal myocardial ablation (PTSMA) effectively reduces gradients, improving patient outcomes.
Area of Science:
- Cardiology
- Genetics
Background:
- Hypertrophic cardiomyopathy (HCM) is a primary myocardial hypertrophy, often familial and genetic.
- The obstructive form (HOCM) presents with dynamic outflow tract obstruction, a leading cause of syncope and sudden cardiac death in young individuals.
- Prognosis in HOCM is challenging to predict despite identified risk factors.
Purpose of the Study:
- To evaluate the efficacy and safety of percutaneous transluminal septal myocardial ablation (PTSMA) as a treatment for obstructive hypertrophic cardiomyopathy (HOCM).
- To assess the impact of PTSMA on outflow tract gradient reduction and long-term patient outcomes.
- To investigate the role of echocardiographic monitoring in optimizing PTSMA and minimizing complications.
Main Methods:
- PTSMA involves alcohol-induced septal branch occlusion to reduce myocardial mass in the outflow tract.
- Echocardiographic monitoring is utilized to optimize the ablation area and assess treatment effectiveness.
- Standard therapies including medical management and surgical myotomy/myectomy are considered alongside PTSMA.
Main Results:
- PTSMA achieves significant outflow tract gradient reduction in over 90% of HOCM patients.
- Further gradient reduction is observed during follow-up due to myocardial remodeling post-ablation.
- Optimized ablation via echocardiography reduced trifascicular block incidence, improving acute and follow-up results.
Conclusions:
- PTSMA is a promising treatment for HOCM, demonstrating significant gradient reduction and improved outcomes.
- Echocardiographic guidance enhances PTSMA efficacy and safety, minimizing the risk of permanent pacemaker implantation.
- Long-term follow-up studies are essential to definitively establish PTSMA's role compared to established treatments for HOCM.
Abstract:
Hypertrophic cardiomyopathy is defined as a primary, sometimes familial and genetically fixed myocardial hypertrophy. In the obstructive form of the disease (HOCM) a dynamic outflow tract obstruction of the left, occasionally also the right ventricle can be found. HOCM is the most frequent cause of stress-induced syncope or sudden cardiac death in younger patients. An individual estimation of prognosis is difficult although several risk factors have been identified. In addition to standard therapy of symptomatic patients (medical treatment with betablockers and calcium-antagonists of verapamil-type as well as surgical myotomy/myectomy) DDD-pacemaker implantation and percutaneous transluminal septal myocardial ablation (PTSMA) by alcohol-induced septal branch occlusion have been introduced. After PTSMA significant outflow tract gradient reduction can be achieved in > 90% of patients. Due to remodeling after circumscribed myocardial necrosis further gradient reduction has been observed during follow-up. Optimization of ablated septal area by echocardiographic monitoring resulted in reduction of the most important complication (trifascicular block with need of permanent pacemaker implantation) and improvement of acute and follow-up results. Long-term follow-up and comparison with established treatment options are necessary to evaluate the definitive importance of the promising new treatment.